Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 34, Issue 4, Pages 785-794Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2020.03.001
Keywords
Follicular lymphoma; Transformed lymphoma; Histologic transformation; Therapy; Prognosis
Categories
Ask authors/readers for more resources
Histologic transformation from follicular lymphoma to aggressive lymphoma historically had a poor prognosis. Routine use of anti-CD20 antibody rituximab has changed the landscape of follicular lymphoma (FL) such that outcomes are improved in select patients, similar to de-novo diffuse large B-cell lymphoma. Several biological and clinical biomarkers can predict risk of transformation, and ongoing research is improving understanding of the biology surrounding the transformation process. This review provides an overview of risk factors, prognosis, and treatment of histologic transformation of FL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
